CONTACT A REP CONTACT
A REP

When people with T2D develop CKD, they head down a dangerous path1

T2D is the #1 cause of kidney failure, which can lead to dialysis or kidney transplant 2,3 | People with T2D and CKD are ~3x more likely to die of CV-related causes ~3x more likely to die of CV-related causes than patients with T2D alone1

Meet 3 patients who could benefit from KERENDIA4,5

Patients with progressing CKD associated with T2D need your help at every stage of their journey

    Kevin, 62 years old4-6

    Works full time and has an active social life. He was diagnosed with T2D 12 years ago, which has led to CKD.

    Kevin, not a real KERENDIA patient.
    alt=””

    Albuminuria/UACR:305 mg/g

    alt=””

    eGFR:55 mL/min/1.73 m2

    Current therapy: Taking multiple T2D standard-of-care medications* and valsartan 160 mg daily for BP

    *Approximately 97% of patients in the FIDELIO-DKD trial were on an antidiabetic medication (insulin [64.1%], biguanides [44%], GLP-1 receptor agonists [7%], SGLT2 inhibitors [5%]).4

    Watch Dr Brunton
    and Dr Wright discuss
    this patient case

    Kevin, 62 years old4-6

    Kevin, not a real KERENDIA patient.

    Works full time and has an active social life. He was diagnosed with T2D 12 years ago, which has led to CKD.

    alt=””

    Albuminuria/UACR:305 mg/g

    alt=””

    eGFR:55 mL/min/1.73 m2

    Current therapy: Taking multiple T2D standard-of-care medications* and valsartan 160 mg daily for BP

    *Approximately 97% of patients in the FIDELIO-DKD trial were on an antidiabetic medication (insulin [64.1%], biguanides [44%], GLP-1 receptor agonists [7%], SGLT2 inhibitors [5%]).4

    Watch Dr Brunton
    and Dr Wright discuss
    this patient case

    Assessing both UACR and eGFR can detect risk of CKD progression earlier 7

    Assess Kevin's risk of CKD progression

    A heat map depicting Kevin’s risk of CKD progression based on his UACR (mg albumin/g creatinine) and eGFR levels

    Watch Dr Feldman
    assess Kevin's risk
    of CKD progression

    Risk of CKD progression based on eGFR and albuminuria categories (green=low to no risk; yellow=moderately increased risk; orange=high risk; red=very high risk).

    Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013; 3(1):63-72. Accessed: https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext

    Risk of CKD progression based on eGFR and albuminuria categories (green=low to no risk; yellow=moderately increased risk; orange=high risk; red=very high risk).

    eGFR categories: eGFR ≥90 mL/min/1.73 m2=normal or high (G1); eGFR 60–89 mL/min/1.73 m2=mildly decreased (G2); eGFR 45–59 mL/min/1.73 m2=mildly to moderately decreased (G3a); eGFR 30–44 mL/min/1.73 m2= moderately to severely decreased (G3b); eGFR 15–29 mL/min/1.73 m2=severely decreased (G4); eGFR <15 mL/min/1.73 m2=kidney failure (G5).

    Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013; 3(1):63-72. Accessed: https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext

    Ken, 62 years old4,5

    Former smoker who had an MI 2 years ago. He was diagnosed with T2D 10 years ago, which has led to his recent diagnosis of CKD.

    Ken, not a real KERENDIA patient.
    alt=””

    Albuminuria/UACR:360 mg/g

    alt=””

    eGFR:50 mL/min/1.73 m2

    alt=””

    BP and HbA1c:Treated for individualized goal

    Serum potassium: 4.2 mEq/L

    Current therapy: Maximum tolerated labeled dose of an ACEi, T2D standard of care,* aspirin monotherapy, and a statin

    *Approximately 97% of patients in the FIDELIO-DKD trial were on an antidiabetic medication (insulin [64.1%], biguanides [44%], GLP-1 receptor agonists [7%], SGLT2 inhibitors [5%]).4

    Ken, 62 years old4,5

    Ken, not a real KERENDIA patient.

    Former smoker who had an MI 2 years ago. He was diagnosed with T2D 10 years ago, which has led to his recent diagnosis of CKD.

    alt=””

    Albuminuria/UACR: 360 mg/g

    alt=””

    eGFR: 50 mL/min/1.73 m2

    alt=””

    BP and HbA1c: Treated for individualized goal

    Serum potassium: 4.2 mEq/L

    Current therapy: Maximum tolerated labeled dose of an ACEi, T2D standard of care,* aspirin monotherapy, and a statin

    *Approximately 97% of patients in the FIDELIO-DKD trial were on an antidiabetic medication (insulin [64.1%], biguanides [44%], GLP-1 receptor agonists [7%], SGLT2 inhibitors [5%]).4

      Patients with high albuminuria are more likely to die from a CV event than patients with normal albumin levels7,8

      A heat map depicting Ken’s risk of CV mortality based on his ACR and eGFR levels

      Risk of CV mortality based on eGFR and albuminuria categories (green=low to no risk; yellow=moderately increased risk; orange=high risk; red=very high risk).

      Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013;3(1):63-72. Accessed: https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext

      Risk of CV mortality based on eGFR and albuminuria categories (green=low to no risk; yellow=moderately increased risk; orange=high risk; red=very high risk).

      Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013; 3(1):63-72. Accessed: https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext

      eGFR alone shows an incomplete picture of your patients' risk of CKD progression7

      A heat map depicting Ken’s risk of CKD progression based on his UACR (mg albumin/g creatinine) and eGFR levels

      Risk of CKD progression based on eGFR and albuminuria categories (green=low to no risk; yellow=moderately increased risk; orange=high risk; red=very high risk).

      Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013; 3(1):63-72. Accessed: https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext

      Risk of CKD progression based on eGFR and albuminuria categories (green=low to no risk; yellow=moderately increased risk; orange=high risk; red=very high risk).

      eGFR categories: eGFR ≥90 mL/min/1.73 m2=normal or high (G1); eGFR 60–89 mL/min/1.73 m2=mildly decreased (G2); eGFR 45–59 mL/min/1.73 m2=mildly to moderately decreased (G3a); eGFR 30–44 mL/min/1.73 m2= moderately to severely decreased (G3b); eGFR 15–29 mL/min/1.73 m2=severely decreased (G4); eGFR <15 mL/min/1.73 m2=kidney failure (G5).

      Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013; 3(1):63-72. Accessed: https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext

      Kathy, 65 years old4-7

      Full-time social worker who enjoys watching musicals with her husband and granddaughter. She has been diagnosed with CKD associated with T2D.

      Kathy, not a real KERENDIA patient.
      alt=””

      Albuminuria/UACR:780 mg/g

      alt=””

      eGFR:35 mL/min/1.73 m2

      alt=””

      eGFR declined
      5 mL/min/1.73 m2
      in the past year

      Current therapy: T2D standard of care,* maximum tolerated labeled dose of an ARB

      *Approximately 97% of patients in the FIDELIO-DKD trial were on an antidiabetic medication (insulin [64.1%], biguanides [44%], GLP-1 receptor agonists [7%], SGLT2 inhibitors [5%]).4

      Watch Dr Bakris and Dr Kramer discuss this patient case

      Kathy, 65 years old4-7

      Kathy, not a real KERENDIA patient.

      Full-time social worker who enjoys watching musicals with her husband and granddaughter. She has been diagnosed with CKD associated with T2D.

      alt=””

      Albuminuria/UACR:780 mg/g

      alt=””

      eGFR:35 mL/min/1.73 m2

      alt=””

      eGFR declined
      5 mL/min/1.73 m2
      in the past year

      Current therapy: T2D standard of care,* maximum tolerated labeled dose of an ARB

      *Approximately 97% of patients in the FIDELIO-DKD trial were on an antidiabetic medication (insulin [64.1%], biguanides [44%], GLP-1 receptor agonists [7%], SGLT2 inhibitors [5%]).4

      Watch Dr Bakris and
      Dr Kramer discuss
      this patient case

        Kathy's UACR and eGFR level put her at very high risk, but there is still time to intervene7

        A heat map depicting Kathy’s risk of CKD progression based on her UACR (mg albumin/g creatinine) and eGFR levels

        Watch Dr Feldman
        assess Kathy's risk
        of CKD progression

        Risk of CKD progression based on eGFR and albuminuria categories (green=low to no risk; yellow=moderately increased risk; orange=high risk; red=very high risk).

        Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013;3(1):63-72. Accessed: https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext

        Risk of CKD progression based on eGFR and albuminuria categories (green=low to no risk; yellow=moderately increased risk; orange=high risk; red=very high risk).

        eGFR categories: eGFR ≥90 mL/min/1.73 m2=normal or high (G1); eGFR 60–89 mL/min/1.73 m2=mildly decreased (G2); eGFR 45–59 mL/min/1.73 m2=mildly to moderately decreased (G3a); eGFR 30–44 mL/min/1.73 m2= moderately to severely decreased (G3b); eGFR 15–29 mL/min/1.73 m2=severely decreased (G4); eGFR <15 mL/min/1.73 m2=kidney failure (G5).

        Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013;3(1):63-72. Accessed: https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext

        Patients like Kathy who have high albuminuria and low eGFR face ~5x greater risk of CV death than patients with T2D alone7,8†

        A heat map depicting Kathy’s risk of CV mortality based on her ACR and eGFR levels

        Risk of CV mortality based on eGFR and albuminuria categories (green=low to no risk; yellow=moderately increased risk; orange=high risk; red=very high risk).

        Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013;3(1):63-72. Accessed: https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext

        Based on the 2005 double-blind placebo-controlled FIELD trial of 200 mg once-daily micronized fenofibrate or placebo in 9795 patients with T2D and mild dyslipidemia. Patients with macroalbuminuria and eGFR 30 to 59 mL/min/1.73 m2 had ~5x greater risk of CV death than patients with no albuminuria and eGFR ≥90 mL/min/1.73 m2.8

        Risk of CV mortality based on eGFR and albuminuria categories (green=low to no risk; yellow=moderately increased risk; orange=high risk; red=very high risk).

        Adapted with permission from KDIGO. Levey AS, de Jong PE, Coresh J, et al. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int Suppl. 2013;3(1):63-72. Accessed: https://www.kisupplements.org/article/S2157-1716(15)31102-3/fulltext

        Based on the 2005 double-blind placebo-controlled FIELD trial of 200 mg once-daily micronized fenofibrate or placebo in 9795 patients with T2D and mild dyslipidemia. Patients with macroalbuminuria and eGFR 30 to 59 mL/min/1.73 m2 had ~5x greater risk of CV death than patients with no albuminuria and eGFR ≥90 mL/min/1.73 m2.

        Next: MOD/MOA

        ACEi=angiotensin-converting enzyme inhibitor; ACR=albumin-to-creatinine ratio; ARB=angiotensin receptor blocker; BP=blood pressure; CKD=chronic kidney disease; CV=cardiovascular; eGFR=estimated glomerular filtration rate; GLP-1=glucagon-like peptide-1; HbA1c=glycated hemoglobin; KDIGO=Kidney Disease: Improving Global Outcomes; MI=myocardial infarction; MOA=mechanism of action; MOD=mechanism of disease; SGLT2=sodium-glucose cotransporter 2; T2D=type 2 diabetes; UACR=urine albumin-to-creatinine ratio.

        INDICATION:

        KERENDIA is indicated to reduce the
        risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)

        IMPORTANT SAFETY INFORMATION

        CONTRAINDICATIONS:

        • Concomitant use with strong CYP3A4 inhibitors
        • Patients with adrenal insufficiency

        WARNINGS AND PRECAUTIONS:

        • Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L

           

          Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium

        MOST COMMON ADVERSE REACTIONS:

        • From the pooled data of 2 placebo-controlled studies, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3.9%), and hyponatremia (1.3% vs 0.7%)

        DRUG INTERACTIONS:

        • Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice
        • Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor and adjust KERENDIA dosage as appropriate
        • Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers

        USE IN SPECIFIC POPULATIONS:

        • Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment
        • Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B)

        Please read the Prescribing Information for KERENDIA.

        References: 1. Afkarian M, et al. J Am Soc Nephrol. 2013;24(2):302-308. 2. Bailey RA, et al. BMC Res Notes. 2014;7:415. 3. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1-S115. 4. KERENDIA (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; July 2021. 5. Bakris GL, et al; FIDELIO-DKD Investigators. N Engl J Med. 2020;383(23):2219-2229. 6. Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. 7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Intl Suppl. 2013;3(1):1-150. 8. Drury PL, et al. Diabetologia. 2011;54(1):32-43.